Abstract
The European Association for the Study of the Liver Hepatocellular Carcinoma (HCC) international meeting held in Geneva in February 2017 focused on the state of the art of HCC management, from diagnosis to treatment and the potential development of clinical research in this field. This report reviews some of the most interesting topics discussed at the meeting such as the role of hepatitis C viral infection treatment with direct-acting antivirals in enhancing HCC risk, current prognostic systems, early diagnosis techniques, curative therapies for early HCC and the systemic treatments for advanced disease with a look into future perspectives.
Keywords:
EASL summit; HCC; HCC diagnosis; HCC treatment.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Antiviral Agents / therapeutic use*
-
Carcinoma, Hepatocellular / diagnosis
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / therapy*
-
Carcinoma, Hepatocellular / virology
-
Catheter Ablation / methods
-
Clinical Trials as Topic
-
Combined Modality Therapy / methods
-
Congresses as Topic
-
Disease Progression
-
Hepacivirus / isolation & purification
-
Hepacivirus / pathogenicity
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology
-
Humans
-
Liver / pathology
-
Liver / virology
-
Liver Neoplasms / diagnosis
-
Liver Neoplasms / pathology
-
Liver Neoplasms / therapy*
-
Liver Neoplasms / virology
-
Neoplasm Staging
-
Prognosis
-
Switzerland
Substances
-
Antineoplastic Agents
-
Antiviral Agents